


Trial Description: Patients with clinically confirmed Marfan syndrome were randomized to irbesartan 300 mg daily vs. placebo.



RESULTS

- Primary efficacy endpoint, mean rate of aortic root dilatation, was 0.53 mm per year in the irbesartan group vs. 0.74 mm per year in the placebo group (p = 0.030)
- Difference in systolic blood pressure at 1 year (irbesartan vs. placebo): -6.3 mm Hg
- Serious adverse events: 24% with irbesartan vs. 23% with placebo

CONCLUSIONS

- Among patients with Marfan syndrome, irbesartan was associated with a reduction in the rate of aortic root dilatation compared with placebo
- Although further investigation is needed, this study supports the use of irbesartan to slow the rate of aortic root dilatation in patients with Marfan syndrome

Mullen M, et al. *Lancet* 2019;394:2263-70